Monday, November 09, 2009 2:34:38 PM
SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ -- Hard To Treat Diseases (HTDS.PK) http://www.htdsmedical.com/, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million. Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide. The comments were made by Novartis' CEO, Daniel Vasella, in an interview with The Wall Street Journal. http://www.chinabiotoday.com/articles/20091103_1
HTDS' Chinese subsidiary, Mellow Hope, is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical for International marketing and sales. Zhejiang Tianyuan Bio-pharmaceutical has been granted a H1N1 license on September 24, 2009 by the Chinese government agency, SFDA.
Terry Yuan, HTDS' President/CEO said "We believe that when you start to appreciate what Novartis' commitment to our partner in China fully means, and the see the large financial commitment to our partner just for the China market, you can begin to appreciate the enormous value to HTDS of our exclusive international marketing and sales relationship with Zhejiang Tianyuan Bio-Pharmaceutical. Further, the more you appreciate this value, the more you will find yourself understanding our value to them when they appointed us exclusive agent for international marketing and sales. As Mellow Hope owns all of registrations, clinical trials and brands for Zhejiang Tianyuan's international markets, the new Novartis-Zhejiang-Tianyuan entity will continue to leverage our assets and expertise in its international market. The Novartis purchase was announced by Novartis-Zhejiang-Tianyuan on November 4, 2009 (see link below) http://www.marketwatch.com/story/novartis-to-buy-85-of-chinese-vaccines-produc er-2009-11-04?siteid=yhoof2. HTDS management, elected not to release this immediately, to allow the HTDS management and its advisors to digest and analyse the long term effects of this transaction for HTDS. HTDS management is very optimistic and foresees its relationship and business with Zhejiang Tianyuan will only be further strengthened by the participation of Novartis."
Novartis reports that it has made the purchase of a majority interest in Zhejiang Tianyuan through proposed acquisition of a majority stake for US$125 million to expand its human vaccines presence in China. Zhejiang Tianyuan is a privately-held vaccines company providing a competitive product portfolio and pipeline in China, where Novartis has a limited vaccines presence. Tianyuan and Novartis are to collaborate on building a vaccines industry leader targeting unmet medical needs in China, the world's third-largest vaccines market. Acquisition of 85% stake in Tianyuan for approximately US$125 million will require Chinese regulatory and government approvals.
Tianyuan is a privately-owned vaccine company offering a range of marketed vaccine products in China and R&D projects focused on various preventable viral and bacterial diseases. Tianyuan has been delivering dynamic and profitable growth, having more than doubled its net sales to approximately US$25 million in 2008.
About Hard To Treat Diseases (HTDS)
HTDS operates 2 medical subsidiaries in Mainland China (Mellow Hope) http://www.mellowhope.com/ and Serbia, Europe (Slavica Bio Chem.) (http://www.slavicabiochem.com/)
Mellow Hope is China-based and the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celesta in.
In Serbia the company's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV.
To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy, however important to the reader and followers of the company please sign up today for free at http://www.minamargroup.com/updates
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM